Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Belzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control arm.
Journal: Journal of the National Cancer Institute
Published: September 08, 2025
A Response to the Letter to the Editor: "Flawed FLAURA Comparisons and Non-Random Biomarker Missingness in US Osimertinib Cohort Study".
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 04, 2025
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort.
Journal: Neuro-oncology advances
Published: May 13, 2025
Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 20, 2024
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: October 08, 2024
The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan).
Journal: Scientific reports
Published: June 26, 2024
Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS).
Journal: Prostate cancer and prostatic diseases
Published: May 23, 2024
Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease.
Journal: European urology
Published: April 09, 2024
UFO registry: final analysis of baseline data from patients with advanced prostate cancer in Asia.
Journal: Therapeutic advances in medical oncology
Published: February 15, 2024
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.
Journal: Ophthalmology
Published: January 18, 2024
Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling.
Journal: Journal of clinical pharmacology
Published: December 21, 2023
Last Updated: 09/26/2026